1. Clinically significant CYP2C inhibition by noscapine but not by glucosamine
- Author
-
Qun-Ying Yue, Erik Eliasson, Stenberg M, Staffan Rosenborg, Otto S, Michèle Masquelier, Leif Bertilsson, and Ostervall J
- Subjects
Adult ,Male ,Noscapine ,CYP2C19 ,Pharmacology ,2-Pyridinylmethylsulfinylbenzimidazoles ,Losartan ,chemistry.chemical_compound ,Young Adult ,Glucosamine ,medicine ,Humans ,Pharmacology (medical) ,Drug Interactions ,CYP2C9 ,Omeprazole ,Cytochrome P-450 CYP2C9 ,biology ,Warfarin ,Cytochrome P450 ,Anticoagulants ,Middle Aged ,Cytochrome P-450 CYP2C19 ,Antitussive Agents ,Phenotype ,chemistry ,biology.protein ,Female ,Aryl Hydrocarbon Hydroxylases ,medicine.drug - Abstract
Noscapine and glucosamine reportedly interact with warfarin. We investigated the effects of these drugs on various cytochrome P450 (CYP) activity markers. Twelve healthy subjects were phenotyped at baseline and during separate treatments with noscapine and glucosamine. Whereas glucosamine had no significant effect on CYP activity, noscapine caused marked inhibition of CYP2C9 (4.9-fold increase in urinary losartan/E3174 ratio) and CYP2C19 (3.6-fold increase in the plasma omeprazole/5-hydroxyomeprazole ratio). Noscapine-dependent inhibition of CYP2C9 may explain the interaction with warfarin.
- Published
- 2010